While PEGylation has been a successful strategy for improving drug half-life, it is also associated with the risk of anaphylaxis and even death of PEGylated drugs. Therefore, our FocalTuningTM platform and relevant products can be applied to all projects aimed at minimizing the risk of PEG-induced anaphylaxis and associated fatalities for each following PEGylated drug on the market.